ABHD17A

Across TCGA pan-cancer cohorts, ABHD17A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ABHD17A data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ABHD17A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ABHD17A expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where ABHD17A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.948	0.727	.005	14	view →
LUAD	DFS	Tertile	All	1.000	0.625	.029	5	view →
CCRCC	DFS	Tertile	All	1.000	0.868	.013	5	view →
GBM	OS	Median	All	0.872	0.758	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ABHD17A–HNSC (OS)

Open the HNSC breakdown →